Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
Exelixis Stock Forecast NASDAQ:EXEL
Price Target and Analyst Ratings
Most Recent Rating
On Nov 03, 2021 "HC Wainwright" gave "$65.00 - $52.00" rating for EXEL. The price target was changed from $19.42 to 11.2%.
Last 30 Days
Historical Ratings
| Date | Rating | Action | Authority | Current Price | Target Price |
|---|---|---|---|---|---|
| 2021-11-03 | $65.00 - $52.00 | Target Lowered by | HC Wainwright | $19.24 | $19.42→11.2% |
| 2021-11-03 | $32.00 - $31.00 | Target Lowered by | Royal Bank of Canada | $19.24 | $19.42→11.2% |
| 2021-11-02 | $30.00 - $29.00 | Target Lowered by | Oppenheimer | $21.88 | $21.70+0.9% |
| 2021-10-06 | Initiated by | Jefferies Financial Group | $20.90 | $20.900.0% | |
| 2021-09-20 | $37.00 - $36.00 | Target Lowered by | Truist Securities | $19.82 | $20.72+0.9% |
| 2021-09-20 | $65.00 | Reiterated by | HC Wainwright | $19.82 | $19.81→4.4% |
| 2021-09-09 | $65.00 | Reiterated by | HC Wainwright | $19.54 | $19.81→0.4% |
| 2021-08-06 | $35.00 - $64.00 | Target Raised by | HC Wainwright | $17.25 | $17.00+1.3% |
| 2021-06-29 | Buy | Reiterated by | HC Wainwright | $17.95 | $47.00 → $35.00 |
| 2021-06-29 | Outperform | Target Lowered by | Oppenheimer | $17.95 | $35.00 → $27.00 |
| 2021-06-28 | Buy | Target Lowered by | Needham & Company LLC | $18.02 | $33.00 → $30.00 |
| 2021-06-15 | Buy | Initiated by | HC Wainwright | $22.64 | $47.00 |
| 2021-04-26 | Equal Weight | Target Lowered by | Morgan Stanley | $24.86 | $27.00 → $26.00 |
| 2021-04-19 | Equal Weight | Target Lowered by | Morgan Stanley | $23.74 | $27.00 → $26.00 |
| 2021-03-30 | Outperform | Initiated by | Credit Suisse Group | $21.97 | $30.00 |
| 2021-03-30 | Outperform | Initiated by | Credit Suisse Group | $21.97 | |
| 2021-03-17 | Outperform | Initiated by | Wolfe Research | $23.15 | $35.00 |
| 2021-03-11 | Outperform | Initiated by | Wolfe Research | $22.82 | |
| 2021-02-16 | Overweight | Target Raised by | Piper Sandler | $21.94 | $33.00 → $36.00 |
| 2021-01-15 | Buy | Reiterated by | William Blair | $23.73 | |
| 2020-12-16 | Equal Weight | Target Lowered by | Morgan Stanley | $20.19 | $29.00 → $27.00 |
| 2020-10-26 | Hold | Target Raised by | Stifel Nicolaus | $21.90 | $26.00 → $27.00 |
| 2020-09-22 | Equal Weight | Target Raised by | Morgan Stanley | $25.61 | $23.00 → $29.00 |
| 2020-09-21 | Outperform | Target Raised by | Oppenheimer | $25.81 | $33.00 → $37.00 |
| 2020-09-21 | Overweight | Target Raised by | Piper Sandler | $25.81 | $30.00 → $33.00 |
| 2020-08-07 | Equal Weight | Target Raised by | Morgan Stanley | $22.36 | $22.00 → $23.00 |
| 2020-07-15 | Equal Weight | Target Raised by | Morgan Stanley | $24.37 | $21.00 → $22.00 |
| 2020-06-02 | Buy | Reiterated by | William Blair | $24.27 | |
| 2020-06-01 | Buy | Initiated by | Oppenheimer | $24.14 | $28.00 → $32.00 |
| 2020-05-14 | Positive - Buy | Target Raised by | SunTrust Banks | $24.76 | $35.00 → $40.00 |
| 2020-05-06 | Target Raised by | Piper Sandler | $26.19 | $23.00 → $30.00 | |
| 2020-05-06 | Equal Weight | Target Raised by | Morgan Stanley | $26.19 | $20.00 → $21.00 |
| 2020-05-06 | Market Perform | Target Raised by | BMO Capital Markets | $26.19 | $20.00 → $27.00 |
| 2020-05-06 | Buy | Reiterated by | Needham & Company LLC | $26.19 | $33.00 |
| 2020-04-21 | Outperform | Target Raised by | Oppenheimer | $24.56 | $25.00 → $28.00 |
| 2020-04-21 | Buy | Reiterated by | Barclays | $24.56 | $30.00 |
| 2020-04-21 | Target Raised by | Guggenheim | $24.56 | $27.00 → $32.00 | |
| 2020-04-20 | Buy | Target Raised by | Needham & Company LLC | $23.58 | $28.00 → $33.00 |
EXEL Stock Trend
Given the current short-term trend, the stock is expected to fall -8.12% during the next 3 months and, with a 90% probability hold a price between $15.67 and $19.63 at the end of this 3-month period.
WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.
Data
| Date | Bottom | Mid | Top |
|---|---|---|---|
| 2021-11-30 | $17.03 | $19.19 | $21.34 |
| 2021-12-01 | $17.00 | $19.16 | $21.31 |
| 2021-12-02 | $16.97 | $19.13 | $21.28 |
| 2021-12-03 | $16.94 | $19.10 | $21.25 |
| 2021-12-06 | $16.91 | $19.07 | $21.22 |
| 2021-12-07 | $16.88 | $19.04 | $21.19 |
| 2021-12-08 | $16.85 | $19.01 | $21.16 |
| 2021-12-09 | $16.82 | $18.98 | $21.13 |
| 2021-12-10 | $16.79 | $18.95 | $21.10 |
| 2021-12-13 | $16.76 | $18.92 | $21.07 |
| 2021-12-14 | $16.73 | $18.89 | $21.04 |
| 2021-12-15 | $16.70 | $18.86 | $21.01 |
| 2021-12-16 | $16.67 | $18.83 | $20.98 |
| 2021-12-17 | $16.64 | $18.80 | $20.95 |
| 2021-12-20 | $16.61 | $18.77 | $20.92 |
| 2021-12-21 | $16.58 | $18.74 | $20.89 |
| 2021-12-22 | $16.55 | $18.71 | $20.86 |
| 2021-12-23 | $16.52 | $18.68 | $20.83 |
| 2021-12-27 | $16.49 | $18.65 | $20.80 |
| 2021-12-28 | $16.46 | $18.62 | $20.77 |
| 2021-12-29 | $16.43 | $18.59 | $20.74 |
| 2021-12-30 | $16.40 | $18.56 | $20.71 |
| 2021-12-31 | $16.37 | $18.53 | $20.68 |
| 2022-01-03 | $16.34 | $18.50 | $20.65 |
| 2022-01-04 | $16.31 | $18.47 | $20.62 |
| 2022-01-05 | $16.28 | $18.44 | $20.59 |
| 2022-01-06 | $16.25 | $18.41 | $20.56 |
| 2022-01-07 | $16.22 | $18.38 | $20.53 |
| 2022-01-10 | $16.19 | $18.35 | $20.50 |
| 2022-01-11 | $16.16 | $18.32 | $20.47 |
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. It focuses on advancing cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development pr... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Join 100 000+ Happy Subscribers
Don't miss out on the runners!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
